We advised the sales agent on the offering

Davis Polk advised the sales agent in connection with a $125 million SEC-registered at-the-market offering by Alector, Inc. of its common stock. Alector’s common stock is listed on the Nasdaq Global Select Market under the symbol “ALEC.”

Alector is a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology and neuroscience, the company is advancing a portfolio of programs that aim to remove toxic proteins, replace missing proteins and restore immune and nerve cell function.

The Davis Polk corporate team included partners Alan F. Denenberg and Beth LeBow and associates Jared Madnick, Ashley Jaworoski and Jonathan P. Trojan-Greenberg. Partner David R. Bauer and associate Ryan Grawe provided intellectual property advice. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post